Please assess the completion status of the following clinical trial:

Trial Title: Iliac, Common and External (ICE) Artery Stent Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \> 21 years.~2. Patient must sign informed consent form.~3. Patient must agree to participate in the study and comply with follow-up requirements.~4. Clinically, all patients must be in Rutherford category 1 to 4.~   Angiographic Inclusion Criteria:~5. Planned stenting (degree of stenosis 70-100%) within the common or external iliac artery. The target lesion must not extend beyond the iliac arteries.~6. Lesion segment starts at the aortic bifurcation and ends at the take off of the common femoral artery (Offset of the iliac circumflex artery beneath the ligamentum inguinale).~7. The length of the lesion should be at least 1 cm and maximally 20 cm (measurement by radiopaque ruler).~8. The degree of target lesion stenosis must be determined by pre-interventional duplex ultrasound or (MR-) angiography.~9. Patency of ipsilateral profunda artery. Ipsi- or contralateral artery lesions of the leg can be treated prior to the treatment of the study lesion.~10. In cases of two or more stenotic regions within the segment, these are considered separate lesions if there is a nonstenotic or only mildly stenotic (\< 30%) segment of at least 2 cm in length between them. Otherwise, they are considered as single lesion. In case of separate lesions, only the proximal lesion will be taken as the target lesion!~11. A tandem lesion that can be treated with one stent will be considered as one lesion.~Exclusion Criteria:~1. Patient is currently participating in another clinical trial~2. Pregnancy or pregnancy planned during study duration~3. Life expectancy less than 2 years~4. Co-morbidities preventing study participation~5. Severe coagulation disorders~6. Current treatment with anticoagulants other than aspirin, ticlopidine, clopidogrel or prasugrel.~7. Active gastric ulcer or gastrointestinal bleeding~8. Thrombotic occlusion of the target vessel within previous 4 weeks.~9. Treatment of target lesion with laser or atherectomy devices.~10. Dialysis dependency.~11. Manifest hyperthyreosis.~12. Known allergy against contrast agent that cannot be adequately controlled by usual premedication.~13. Known heparin intolerance.~14. Known paclitaxel intolerance.~    Angiographic:~15. Target lesion extends into the femoral artery.~16. Symptomatic untreated inflow lesion \> 70% in ipsilateral iliac arteries. Pretreatment of iliac stenosis is possible.~17. Target Lesion is in aortic bifurcation and needs treatment with kissing balloon technique~18. Lesion in abdominal aorta that needs treatment.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Balloon expandable stent arm (Type: ACTIVE_COMPARATOR): First placement of the sheath and successful passage of a 0.018 or 0.035 guidewire via the sheath across the target lesion in the iliac arteries was required. Consecutively the balloon-expandable stent (Visi-Pro™, ev3 Endovascular, Inc., Plymouth, MN, USA), which was premounted on a balloon catheter, was deployed by inflation of the balloon. The nominal stent diameter had to approximate the reference vessel diameter of the target lesion. Postdilation was permitted
- Selfexpanding stent arm (Type: ACTIVE_COMPARATOR): First placement of the sheath and successful passage of a 0.018 or 0.035 guidewire via the sheath across the target lesion in the iliac arteries was required. Consecutively the the self-expanding stent (Protege™, ev3 Endovascular, Inc., Plymouth, MN, USA), which had to exceed in the nominal diameter the reference vessel diameter at least by 1 mm, was released. Postdilation was mandatory. The inflated postdilation-balloon should approximate the reference vessel diameter.

Based on this trial design, predict the completion outcome and termination type (if applicable).